Sumitomo Mitsui Trust Group
RUBY

Sumitomo Mitsui Trust Group’s Rubius Therapeutics, Inc RUBY Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,436,013
Closed -$13.6M – 1155
2019
Q4 		$13.6M Sell
1,436,013
-20,829
-1% -$201K 0.01% 708
2019
Q3 		$11.4M Buy
1,456,842
+215,543
+17% +$2.51M 0.01% 716
2019
Q2 		$19.5M Buy
1,241,299
+739,449
+147% +$11.9M 0.02% 657
2019
Q1 		$9.08M Buy
+501,850
New +$7.7M 0.01% 695

Other funds holding RUBY

Flagship Pioneering
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arch Venture Management
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Harbourvest Partners
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group's RUBY Position: Q1 2020 in Review

Sumitomo Mitsui Trust Group sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2020, closing a stake of 1,436,013 shares — an estimated $13.6M sold.

Sumitomo Mitsui Trust Group first reported a position in RUBY in Q1 2019 and held it in 4 quarters. The position peaked at $19.5M in Q2 2019. 76 funds tracked by Wall St. Rank hold RUBY as of Q1 2020.

  • Sumitomo Mitsui Trust Group reported no remaining Rubius Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 1,436,013 Rubius Therapeutics, Inc shares in Q1 2020, an estimated $13.6M.
  • Sumitomo Mitsui Trust Group first reported a position in Rubius Therapeutics, Inc in Q1 2019 and held it in 4 quarters.
  • Sumitomo Mitsui Trust Group's Rubius Therapeutics, Inc position peaked at $19.5M in Q2 2019.
  • 76 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2020.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q1 2020, filed 27 Apr 2020.